Neumann 2012.

Methods	Randomised clinical trial
Participants	Country: multicentric (Europe) Period of recruitment: 2005‐2008 Number randomised: 138 Post‐randomisation dropouts: 3 (2.2%) Revised sample size: 135 Reasons for post‐randomisation dropouts: not transplanted or no study medication Average age (years): 54 Females: 41 (30.4%) Primary transplantation: 135 (100.0%) Reason for transplantation Alcohol‐related cirrhosis: 0 (0.0%) Viral‐related cirrhosis: 135 (100.0%) Autoimmune disease‐related cirrhosis: 0 (0.0%) HCC: 0 (0.0%) Others: 0 (0.0%) Maintenance immunosuppression used during induction immunosuppression: tacrolimus Altered immunosuppression after withdrawal: no
Interventions	Group 1: daclizumab (n = 67) Further details: daclizumab 2 mg/kg two doses: the first dose was given during the anhepatic period and the second dose between days 7 and 10 Group 2: glucocorticosteroids (n = 68) Further details: glucocorticosteroids (no further details) were given at a bolus dose of 500 mg in the perioperative period followed by tapered doses of 15‐20 mg/day during month 1, 10‐15 mg/day during month 2, 5‐10 mg/day during month 3, then discontinued
Outcomes	Outcomes reported: mortality at maximal follow‐up, graft failure at maximal follow‐up, any adverse events (number of people), graft rejection (any), graft rejection (requiring treatment) Follow‐up (months): 12
Notes	Source of funding (quote): "Astellas Pharma Europe Ltd. provided funding for the study" Trial name/trial registry number: not stated Attempts were made to contact the authors in August 2019.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "RANCODE (version 3.6) was used to generate the randomization sequence"
Allocation concealment (selection bias)	Low risk	Quote: "Allocation to treatment arms was performed using sealed sequentially numbered randomization envelopes provided by the study sponsor"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "prospective, randomized, open‐label, parallel arm study"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "prospective, randomized, open‐label, parallel arm study"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: there were post‐randomisation dropouts. It was not clear whether these could be related to the interventions
Selective reporting (reporting bias)	Low risk	Comment: no pre‐published protocol was available, but the authors reported on mortality, graft loss, and adverse events
Other bias	Low risk	Comment: no other bias noted